Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study
Descripción general
Resumen del artículo
In a study of older men with advanced prostate cancer in Ontario, Canada, researchers found that the type of doctor initially prescribing hormone therapy significantly influenced whether patients received additional, life-extending treatments. Older patients were also less likely to receive these intensified treatments, even when medically appropriate.
Explícamelo como si tuviera cinco años
The study found that men with prostate cancer are more likely to get stronger treatments if their first hormone therapy is prescribed by a cancer specialist, and if they are younger. This matters because these extra treatments help people live longer.
Posibles conflictos de intereses
Several authors disclosed receiving personal fees, research funding, grants, and/or holding advisory board positions for various pharmaceutical companies, including those manufacturing treatments for prostate cancer (e.g., Janssen, Bayer, Astellas, Merck, Pfizer). These potential conflicts should be considered when interpreting the findings.
Limitaciones identificadas
Explicación de la calificación
This is a well-conducted population-based study that identifies important variations and potential disparities in prostate cancer care. The large sample size and use of real-world data are strengths, but limitations regarding data granularity and generalizability to younger patients prevent a higher rating.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →